

By Senator Rodriguez

40-00575B-26

20261070

20 Be It Enacted by the Legislature of the State of Florida:

22 Section 1. Subsection (9) is added to section 110.12303,
23 Florida Statutes, to read:

110.12303 State group insurance program; additional
benefits; price transparency program; reporting.—

26 (9) (a) For state group health insurance plan policies
27 issued on or after January 1, 2027, the department shall provide
28 coverage for all of the following evidence-based strategies for
29 the treatment and management of obesity and related conditions,

40-00575B-26

20261070

30 as prescribed by a licensed provider:

31 1. Intensive health behavioral and lifestyle intervention.

32 2. FDA-approved weight management medications.

33 (b) Coverage criteria for FDA-approved weight management

34 medications may not be more restrictive than the United States

35 Food and Drug Administration-approved indications for such

36 medications. Coverage for intensive health behavioral and

37 lifestyle treatment may include interventions certified or

38 recognized by the United States Centers for Disease Control and

39 Prevention or recommended by current clinical standards of care.

40 Services may be provided in an office setting, through

41 telehealth, or in community-based settings to support patient

42 access and needs.

43 (c) The department shall adopt protocols and criteria for

44 such coverage by January 1, 2027, which must include, but are

45 not limited to, that the employee:

46 1. Is enrolled in one of the state group health insurance

47 plans or HMO plans participating under this section;

48 2. Is 18 years of age or older;

49 3. Was referred and is supervised by an in-network licensed

50 provider;

51 4. Has consented to provide personal and medical

52 information to the department, including medical records

53 documenting body mass index or weight-related comorbidities;

54 5. Has received a clinical diagnosis of obesity by an in-

55 network licensed provider;

56 6. Is required to participate in intensive health

57 behavioral and lifestyle intervention; and

58 7. Meets any additional clinical and participation

40-00575B-26

20261070

59 requirements to manage the cost of coverage.

60 (d) As used in this subsection, the term:

61 1. "FDA-approved weight management medication" means any
62 glucagon-like peptide-1 (GLP-1) agonist medication approved by
63 the United States Food and Drug Administration with an
64 indication for chronic weight management in patients with an
65 obesity diagnosis.

66 2. "Intensive health behavioral and lifestyle intervention"
67 means an evidence-based, intensive, multicomponent behavioral or
68 lifestyle modification intervention designed to support healthy
69 weight management as recommended by current clinical standards
70 of care. Interventions include obesity screening, nutrition
71 assessment, nutrition diagnosis, nutrition intervention,
72 nutrition monitoring and evaluation, and behavioral counseling
73 and therapy aimed at weight loss through lifestyle
74 modifications, such as changes in diet and increased physical
75 activity. Interventions may be provided in office, through
76 telehealth, or in community-based settings to support patient
77 access and needs. Therapy for obesity must be delivered in
78 accordance with applicable national clinical standards of care,
79 using evidence-based behavioral counseling frameworks.

80 (e) By January 15 of each year, the department shall submit
81 a report to the Governor, the President of the Senate, and the
82 Speaker of the House of Representatives. The report must include
83 the participation level and cost savings to both the enrollee
84 and the state resulting from implementation of this subsection.

85 Section 2. This act shall take effect July 1, 2026.